In terms of the provisions of the Code of Conduct to Regulate, Monitor and Report trading by Designated Persons and their immediate relative (‘the Code’), Medicamen Biotech has informed that the ‘Trading Window’ for dealing in the securities of the Company will be closed for all Directors / Designated Persons /Connected Persons under the Code from April 01, 2025 and the same will remain closed till 48 hours after the declaration of Audited Financial Results (Standalone & Consolidated) for the quarter and year ended on March 31, 2025, to the public. Accordingly, all Directors / Designated Persons / Connected Persons under the Code have been advised not to trade in the securities of the Company during the aforesaid period of closure of Trading Window. The date of meeting of the Board of Directors of the Company, to approve the Audited Financial Results (Standalone & Consolidated) of the Company for the aforesaid period will be intimated separately in due course of time.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1654.70 |
| Dr. Reddys Lab | 1232.00 |
| Cipla | 1229.60 |
| Zydus Lifesciences | 915.45 |
| Lupin | 2332.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: